All In MedTech

Device Trial Radar · NCT02186223

The Angel® Catheter Pivotal Clinical Trial

The Angel® Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects

Last checked: Nov 20, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Jan 2015

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
BiO2 MedicalNot on our public-company list
Sponsor type
Industry
Collaborators
CardioMed Device Consultants, LLC; Intrinsic Imaging, LLC; Novella Clinical
First posted
Jul 10, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to standard pharmacological therapy (anticoagulation).

Conditions

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Venous Thromboembolism
  • Trauma

Interventions

  • The Angel® CatheterDevice

    The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom From Clinically Significant PE or Fatal PE During Treatment PeriodTime frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever is first (maximum of 33 assessment days with an anticipated average of 7 days)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.